• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma.

作者信息

Fei Kailun, Xu Jiachen, Wang Zhijie

机构信息

State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

出版信息

Transl Lung Cancer Res. 2020 Jun;9(3):833-836. doi: 10.21037/tlcr-20-570.

DOI:10.21037/tlcr-20-570
PMID:32676348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7354157/
Abstract
摘要

相似文献

1
A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma.免疫检查点抑制剂疗法的新篇章：始于晚期肺鳞状细胞癌。
Transl Lung Cancer Res. 2020 Jun;9(3):833-836. doi: 10.21037/tlcr-20-570.
2
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.晚期非小细胞肺癌患者接受免疫检查点抑制剂治疗时抗生素的预测影响：抗生素免疫检查点抑制剂在晚期 NSCLC 中的应用。
Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.
3
Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.日本晚期肺鳞状细胞癌的最新治疗策略。
Int J Clin Oncol. 2019 May;24(5):461-467. doi: 10.1007/s10147-019-01424-y. Epub 2019 Mar 7.
4
Case of advanced pulmonary squamous cell carcinoma cured by resection through preoperative induction of immune checkpoint inhibitor.免疫检查点抑制剂术前诱导治疗晚期肺鳞癌并手术切除 1 例
Thorac Cancer. 2018 Apr;9(4):495-497. doi: 10.1111/1759-7714.12592. Epub 2018 Feb 8.
5
Best practice in the treatment of advanced squamous cell lung cancer.晚期肺鳞状细胞癌的最佳治疗实践。
Ther Adv Respir Dis. 2015 Oct;9(5):224-35. doi: 10.1177/1753465815581147. Epub 2015 Apr 22.
6
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
7
[Clinical research on immune checkpoint and head and neck squamous cell carcinoma].[免疫检查点与头颈部鳞状细胞癌的临床研究]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Sep 7;52(9):717-720. doi: 10.3760/cma.j.issn.1673-0860.2017.09.017.
8
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.免疫检查点抑制剂治疗晚期肾细胞癌：现有经验与未来方向。
Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151.
9
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.免疫检查点抑制剂作为晚期非小细胞肺癌的一线及挽救治疗
Future Oncol. 2016 Aug;12(15):1805-22. doi: 10.2217/fon-2016-0086. Epub 2016 Jun 8.
10
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report.纳武利尤单抗联合卡铂和紫杉醇作为一线治疗方案用于程序性死亡配体1高表达的晚期肺鳞状细胞癌：一例报告
Cureus. 2019 Oct 10;11(10):e5881. doi: 10.7759/cureus.5881.

本文引用的文献

1
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.一线治疗晚期表皮生长因子受体突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
BMJ. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460.
2
First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.晚期或转移性鳞状非小细胞肺癌患者的一线治疗：系统评价与网状Meta分析
J Thorac Dis. 2018 Dec;10(12):6677-6694. doi: 10.21037/jtd.2018.11.87.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.纳武利尤单抗对比多西他赛用于治疗既往接受过治疗的晚期非小细胞肺癌（CheckMate 017 和 CheckMate 057）：3 年更新结果及肝转移患者的结局。
Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.
5
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
6
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
7
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
8
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.阿特珠单抗对比多西他赛用于治疗既往接受过治疗的非小细胞肺癌患者（POPLAR）：一项多中心、开放标签、2 期随机对照临床试验。
Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
9
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
10
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.